Earth Science Tech (OTCMKTS:ETST) versus Cytokinetics (NASDAQ:CYTK) Critical Survey

Cytokinetics (NASDAQ:CYTK) and Earth Science Tech (OTCMKTS:ETST) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Earnings and Valuation

This table compares Cytokinetics and Earth Science Tech”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$3.13 million	1,761.84	-$526.24 million	($5.40)	-9.75
Earth Science Tech	$11.95 million	4.40	$810,000.00	N/A	N/A

Earth Science Tech has higher revenue and earnings than Cytokinetics.

Profitability

This table compares Cytokinetics and Earth Science Tech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-17,398.82%	N/A	-55.97%
Earth Science Tech	6.67%	23.85%	13.57%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Cytokinetics and Earth Science Tech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	0	4	11	0	2.73
Earth Science Tech	0	0	0	0	N/A

Cytokinetics presently has a consensus price target of $80.67, indicating a potential upside of 53.18%. Given Cytokinetics’ higher possible upside, research analysts plainly believe Cytokinetics is more favorable than Earth Science Tech.

Volatility and Risk

Cytokinetics has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Earth Science Tech has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500.

Summary

Earth Science Tech beats Cytokinetics on 6 of the 9 factors compared between the two stocks.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

About Earth Science Tech

Earth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.